Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Is there some data (even if limited) regarding the medical advice as far as when to receive another vaccine dose?

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

Ask the Doctor Question:

Since there now are a few treatments under way for the pre-exposure prophylaxis treatment for high-risk patients, such as AZD7442, Regeneron and the upcoming Molnupirar, is there some data (even if limited) regarding the medical advice as far as when to receive another dose?

Answer: We’re not sure what you mean by another dose? We’re guessing perhaps you mean another dose of the vaccine?

Currently, there are no drugs/therapies with EUA from the FDA for pre-exposure prophylaxis. Regeneron is approved for prophylaxis ONLY in the case of known exposure to COVID-19 right now. However, trials are beginning to look at whether or not their antibody cocktail will be useful prophylactically. The problem with Regeneron is that it is short- acting, so the antibodies don’t hang around very long (about a month is estimated on average). The upcoming AZD7442 is very promising as it is a long-acting monoclonal antibody cocktail that is only given every 6-12 months. However, it is again not yet approved or available, but you can read more about this one here.

Right now, your best bet is to make sure you have received all three shots of the vaccine (including the booster), continue to take precautions as if you were never vaccinated, and make sure you have completed your COVID-19 checklists for your personalized action plan.